Company Summary
Chimera Bioengineering was acquired by Vaxanix in May of 2024. Chimera’s research comes mainly from its GOLD platform, a technology that leverages native T cell RNA-based gene regulation circuits to control transgenic payload production by chimeric antigen receptor (CAR) T cells. Using GOLD, Chimera is engineering CAR-T cell therapies that target and weaken tu- mor microenvironments, making the medicinal payload of the CAR-T cells more powerful.